Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Facts, Views & Vision in Obgyn|December 8, 2025
Robotic secondary cytoreduction in recurrent ovarian cancer: a tailored approach for kidney transplant recipientsSilvio Andrea Russo, Riccardo Oliva, Camilla Certelli, et al.
Gynecologic Oncology|October 15, 2025
Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysisVictoria M Ettorre, Stefania Bellone, Natalia Buza, et al.
Gynecologic Oncology|May 7, 2025
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analysesVictoria M Ettorre, Stefania Bellone, Michelle Greenman, et al.
Annals of Surgical Oncology|July 16, 2025
Laparoscopic Cytoreduction for Benign Multicystic Mesothelioma: A Comprehensive Description of a Pelvic Space-Oriented PeritonectomyMatteo Aulicino, Carlo Abatini, Federica Ferracci, et al.
Cancer Research Communications|August 27, 2025
Preclinical activity of Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate targeting TROP2, in poorly differentiated endometrial carcinomasNiccolo G Santin, Namrata Sethi, Stefania Bellone, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 18, 2025
Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical modelsVictoria M Ettorre, Beatrice Conca, Cem Demirkiran, et al.
European Journal of Cancer (Oxford, England : 1990)|April 16, 2023
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classificationEmanuele Perrone, Ilaria Capasso, Francesca De Felice, et al.
Gynecologic Oncology|June 29, 2025
Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcomaMichelle Greenman, Stefania Bellone, Cem Demirkiran, et al.
Journal of Personalized Medicine|October 25, 2024
Robotic Rectosigmoid Resection with Totally Intracorporeal Colorectal Anastomosis (TICA) for Recurrent Ovarian Cancer: A Case Series and Description of the TechniqueValerio Gallotta, Luca Palmieri, Francesco Santullo, et al.
Gynecologic Oncology|July 15, 2026
Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinomaSarah Ottum, Namrata Sethi, Stefania Bellone, et al.
Pageof 6